# An Update on the Correlation Between Neuroimmunomodulation, Photodynamic Therapy (PDT), and Wound Healing: The Role of Mast Cells

**Authors:** Montserrat Fernandez-Guarino, Luis Alonso-Mtz de Salinas, Jorge Naharro-Rodriguez, Stefano Bacci

PMC · DOI: 10.3390/biomedicines14020280 · Biomedicines · 2026-01-27

## TL;DR

This review explores how photodynamic therapy affects wound healing by interacting with the nervous system and immune cells, particularly mast cells.

## Contribution

The paper highlights the novel role of mast cells as neuroimmune intermediaries in photodynamic therapy's effect on chronic wound healing.

## Key findings

- Mast cells act as key neuroimmune intermediaries by releasing inflammatory mediators that influence wound tissue and nerve fibers.
- Photodynamic therapy modulates wound healing through cellular and molecular mechanisms linked to neuroimmunomodulation.
- Neuropeptides from peripheral nerves further modulate immune activity and tissue repair during wound healing.

## Abstract

This review presents some aspects of the complex relationship between neuroimmunomodulation, photodynamic therapy, and wound healing. This relationship is important because photodynamic therapy, currently used to treat chronic wounds, has numerous effects on so-called neuroimmunomodulation, or the influence the nervous system has on immune cells. Consequently, the cellular and molecular mechanisms of wound healing and the alterations of these mechanisms that lead to the formation of chronic wounds are first considered. This view is subsequently broadened to include the effects produced by neuroimmunomodulation throughout the various phases of wound healing and the alterations produced in chronic wounds. Throughout the above, the role of mast cells, the main inflammatory cells that play a key role in wound healing, is highlighted. In this context, mast cells, located in close anatomical and functional proximity to peripheral nerve endings, act as key neuroimmune intermediaries. Upon activation, mast cells release inflammatory mediators that directly influence wound tissue and sensitize nearby nerve fibers. In turn, peripheral nerves release neuropeptides that further modulate immune cell activity, vascular responses, and tissue repair processes. All of this is in turn linked to the clinical evidence that photodynamic therapy, by virtue of the cellular and molecular mechanisms involved, can indeed be considered involved in the healing of chronic wounds.

## Full-text entities

- **Genes:** CA2 (carbonic anhydrase 2) [NCBI Gene 760] {aka CA-II, CAC, CAII, Car2, HEL-76, HEL-S-282}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TACR2 (tachykinin receptor 2) [NCBI Gene 6865] {aka NK2R, NKNAR, SKR, TAC2R}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, Ccl4 (C-C motif chemokine ligand 4) [NCBI Gene 20303] {aka AT744.1, Act-2, MIP-1B, Mip1b, Scya4}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, Col6a1 (collagen, type VI, alpha 1) [NCBI Gene 12833] {aka Col6a-1}, NT3 [NCBI Gene 4877], Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, Chek1 (checkpoint kinase 1) [NCBI Gene 12649] {aka Chk1, rad27}, CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818] {aka CAMK, CAMK-II, CAMKG, MRD59}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, Calca (calcitonin/calcitonin-related polypeptide, alpha) [NCBI Gene 12310] {aka CA, CGRP-1, CGRP1, Calc, Calc1, Cgrp}, Npy (neuropeptide Y) [NCBI Gene 109648] {aka 0710005A05Rik}, INHBE (inhibin subunit beta E) [NCBI Gene 83729], NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, Col4a1 (collagen, type IV, alpha 1) [NCBI Gene 12826] {aka Bru, Col4a-1, Raw, Svc}, Ccnb1 (cyclin B1) [NCBI Gene 268697] {aka Ccnb1-rs1, Ccnb1-rs13, CycB1, Cycb-4, Cycb-5, Cycb1-rs1}, NTF3 (neurotrophin 3) [NCBI Gene 4908] {aka HDNF, NGF-2, NGF2, NT-3, NT3}, Dct (dopachrome tautomerase) [NCBI Gene 13190] {aka DT, TRP-2, TRP2, Tyrp-2, Tyrp2, slaty}, Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 14825] {aka Fsp, Gro1, KC, Mgsa, N51, Scyb1}, NPY (neuropeptide Y) [NCBI Gene 4852] {aka PYY4}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Cxcl2 (C-X-C motif chemokine ligand 2) [NCBI Gene 20310] {aka CINC-2a, GROb, Gro2, MIP-2, MIP-2a, Mgsa-b}, GRP (gastrin releasing peptide) [NCBI Gene 2922] {aka BN, GRP-10, preproGRP, proGRP}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, VIP (vasoactive intestinal peptide) [NCBI Gene 7432] {aka PHM27}, CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, Vip (vasoactive intestinal peptide) [NCBI Gene 117064] {aka vip/phi27}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, ADCYAP1 (adenylate cyclase activating polypeptide 1) [NCBI Gene 116] {aka PACAP}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, Tyr (tyrosinase) [NCBI Gene 22173] {aka Oca1, albino, c, skc35}, UCHL1 (ubiquitin C-terminal hydrolase L1) [NCBI Gene 7345] {aka HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], Cxcl5 (C-X-C motif chemokine ligand 5) [NCBI Gene 20311] {aka AMCF-II, Cxcl6, ENA-78, GCP-2, LIX, Scyb5}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Cdk1 (cyclin dependent kinase 1) [NCBI Gene 12534] {aka Cdc2, Cdc2a, p34<CDC2>}, Cxcl3 (C-X-C motif chemokine ligand 3) [NCBI Gene 330122] {aka Dcip1, Gm1960}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, ADRB2 (adrenoceptor beta 2) [NCBI Gene 154] {aka ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, TACR1 (tachykinin receptor 1) [NCBI Gene 6869] {aka NK1R, NKIR, SPR, TAC1R}, SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606] {aka BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3}, Col4a2 (collagen, type IV, alpha 2) [NCBI Gene 12827] {aka Col4a-2}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, Tyrp1 (tyrosinase-related protein 1) [NCBI Gene 22178] {aka Oca3, TRP-1, TRP1, Tyrp, b, brown}, TGFA (transforming growth factor alpha) [NCBI Gene 7039] {aka TFGA}
- **Diseases:** hypertension (MESH:D006973), pain (MESH:D010146), fungal, viral, immunological, or inflammatory infections (MESH:D014777), skin lesions (MESH:D012871), neurodegenerative diseases (MESH:D019636), CW (MESH:D014947), diabetic foot ulcers (MESH:D017719), Inflammation (MESH:D007249), fibrosis (MESH:D005355), actinic and non-oncologic keratoses (MESH:D055623), cytotoxic (MESH:D064420), Chronic ulcers (MESH:D014456), MCT (MESH:D000090362), psychiatric disorders (MESH:D001523), Infections (MESH:D007239), diabetes (MESH:D003920), cutaneous damage (MESH:D045743), cancer (MESH:D009369), venous ulcers (MESH:D014647), bacterial (MESH:D001424), bleeding (MESH:D006470), squamous cell carcinoma (MESH:D002294), Tissue injury (MESH:D017695), disorders (MESH:D009358), chronic (MESH:D002908), burn injuries (MESH:D002056), hypoxia (MESH:D000860), Healing (MESH:C563468), necrosis (MESH:D009336), oncological (MESH:D000072716), basal cell carcinoma (MESH:D002280)
- **Chemicals:** oxygen (MESH:D010100), proto-porphyrin IX (MESH:C028025), CW (-), superoxide anions (MESH:D013481), histamine (MESH:D006632), singlet oxygen (MESH:D026082), ALA (MESH:D000622), heme (MESH:D006418), Polypeptide (MESH:D010455), lipid (MESH:D008055), 5-ALA (MESH:C000614854), melanin (MESH:D008543), ATP (MESH:D000255), methicillin (MESH:D008712), serotonin (MESH:D012701), NO (MESH:D009569), hydroxyl radicals (MESH:D017665), Calcium (MESH:D002118), ROS (MESH:D017382)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Staphylococcus aureus (species) [taxon 1280], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938672/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938672/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938672/full.md

---
Source: https://tomesphere.com/paper/PMC12938672